This Article Full Text Full Text (PDF) Supplementary Data All Versions of this Article: 0008-5472.CAN-09-1576v1 69/22/8645    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Pardo, O. E. Articles by Seckl, M. J. PubMed PubMed Citation Articles by Pardo, O. E. Articles by Seckl, M. J.

The Fibroblast Growth Factor Receptor Inhibitor PD173074 Blocks Small Cell Lung Cancer Growth In vitro and In vivo

¹ Lung Cancer Biology Group, Cancer Research UK Laboratories and ² Molecular Therapy Group, Clinical Sciences Centre, Hammersmith Hospital Campus of Imperial College London; ³ In Situ Hybridisation and ⁴ Experimental Pathology Laboratories, Cancer Research UK London Research Institute; and ⁵ Institute of Cancer, Barts and The London, School of Medicine and Dentistry, London, United Kingdom

Requests for reprints: Michael J. Seckl, Imperial College Faculty of Medicine, Du Cane Road, London W12 ONN, United Kingdom. Phone: 44-20-8846-1421; Fax: 44-20-7561-1891; E-mail: m.seckl{at}imperial.ac.uk.

Lung cancer is the commonest cancer killer. Small cell lung cancer (SCLC) is initially chemosensitive, but rapidly relapses in a chemoresistant form with an overall survival of <5%. Consequently, novel therapies are urgently required and will likely arise from an improved understanding of the disease biology. Our previous work showed that fibroblast growth factor-2 induces proliferation and chemoresistance in SCLC cells. Here, we show that the selective fibroblast growth factor receptor (FGFR) inhibitor PD173074 blocks H-510 and H-69 SCLC proliferation and clonogenic growth in a dose-dependent fashion and prevents FGF-2–induced chemoresistance. These effects correlate with the inhibition of both FGFR1 and FGFR2 transphosphorylation. We then determined the efficacy of daily oral administration of PD173074 for 28 days in two human SCLC models. In the H-510 xenograft, tumor growth was impaired similar to that seen with single-agent cisplatin administration, increasing median survival compared with control sham–treated animals. Crucially, the effect of cisplatin was significantly potentiated by coadministration of PD173074. More dramatically, in H-69 xenografts, PD173074 induced complete responses lasting >6 months in 50% of mice. These effects were not a consequence of disrupted tumor vasculature but instead correlated with increased apoptosis (caspase 3 and cytokeratin 18 cleavage) in excised tumors. Moreover, in vivo imaging with 3'-deoxy-3'-[¹⁸F]fluorothymidine–positron emission tomography ([¹⁸F]FLT-PET) showed decreased intratumoral proliferation in live animals treated with the compound at 7 to 14 days. Our results suggest that clinical trials of FGFR inhibitors should be undertaken in patients with SCLC and that [¹⁸F]FLT-PET imaging could provide early in vivo evidence of response. [Cancer Res 2009;69(22):8645–51]

Key Words: FGF receptor • inhibitor • SCLC • PET